

I hereby certify that on October 11, 2011, which is the date I am signing this certificate, I am transmitting this correspondence and all identified attachments electronically to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

/Grace Kim/

Grace Kim

Applicant: **BAMDAD, Cynthia C.**  
 Serial No.: **10/564,981**  
 Filed: **January 13, 2006**  
 Confirmation No.: **4121**  
 Title: **METHODS FOR DIAGNOSIS AND TREATMENT OF CANCER**  
 Examiner: **MCDOWELL, Brian E.**  
 Art Unit: **1624**  
 Attorney Docket No.: **13150-70090US**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents are enclosed.

#### Non-Patent Documents:

|  |
|--|
| CHEN et al., "Labeling of Proteins with [ <sup>35</sup> S] Methionine and/or [ <sup>35</sup> S] Cysteine in the Absence of Cells," <i>Analytical Biochemistry</i> , 269:179-188, 1999.                 |
| FRALEY et al., "New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids", <i>Trends in Biochemical Sciences</i> , 6:77-80, 1981. (abstract only) |
| GREGORIADIS, "Liposomes for drugs and vaccines," <i>Trends in Biotechnology</i> , 3(9):235-241, 1985. (abstract only)  |

|  |
|--|
| HIEKEN et al., "beta3 Integrin Expression in Melanoma Predicts Subsequent Metastasis," <i>Journal of Surgical Research</i> , 63(1):169-173(5), 1996. (abstract only)   |
| HORTON, "The $\alpha\beta 3$ Integrin "Vitronectin Receptor," <i>Int. J. Biochem. Cell Biol.</i> , 29(5):721-725, 1997.  |
| KUFE et al., "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors," <i>Hybridoma</i> , 3(3):223-232, 1984. (abstract only)   |
| LIGTENBERG et al., "Cell-associated Episialin is a Complex Containing Two Proteins Derived from a Common Precursor", <i>The Journal of Biological Chemistry</i> , 267(9):6171-6177, 1992.  |
| MAO et al., "Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer," <i>Int. J. Oncol.</i> , 18(3):587-591, 2001. (abstract only)   |
| MEERZAMAN et al., "Involvement of the MAP kinase ERK2 in MUC1 mucin signaling," <i>Am. J. Physiol. Lung Cell Mol. Physiol.</i> , 281:L86-L91, 2001.  |
| PEGRAM et al., "Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment," <i>Journal of Clinical Oncology</i> , 16:2659-2671, 1998. (abstract only) |
| ROSS et al., "The HER-2/neu Oncogene in breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy," <i>Stem Cells</i> , 16:413-428, 1998.  |
| SAWHNEY et al., "Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly( $\alpha$ -hydroxy acid) Diacrylate Macromers," <i>Macromolecules</i> , 26:581-587, 1993.   |
| SCHNEIDER et al., "nm23 expression in advanced and borderline ovarian carcinoma," <i>Anticancer Res.</i> , 16(3A):1197-1202, 1996. (abstract only)   |
| SPICER et al., "Molecular Cloning and Analysis of the Mouse Homologue of the Tumor-associated Mucin, MUC1, Reveals Conservation of Potential O-Glycosylation Sites, Transmembrane, and Cytoplasmic Domains and a Loss of Minisatellite-like Polymorphism," <i>The Journal of Biological Chemistry</i> , 266(23):15099-15109, 1991.       |
| TREON et al., "MUC-1 Core Protein is Expressed on Multiple Myeloma Cells and is Induced by Dexamethasone", <i>Blood</i> , 93(4):1287-1298, 1990. (abstract only)   |
| VAILHE et al., "In vitro angiogenesis is modulated by the mechanical properties of fibrin gels and is related to $\alpha(v)\beta 3$ integrin localization," <i>In Vitro Cell Dev. Biol. Anim.</i> , 33(10):763-773, 1997. (abstract only)  |
| VARNER et al., "Integrins and cancer," <i>Current Opinion in Cell Biology</i> , 8:724-730, 1996.   |

#### U.S. Patent Documents:

|  |
|--|
| US 2003/0144350 A1, Stevenson et al., July 31, 2003. |
| US 6,596,723 B1, Watkins et al., July 22, 2003.      |
| US 6,964,967 B2, Huang et al., November 15, 2005.    |

#### Foreign Patent Documents:

|  |
|--|
| WO 92/07000, Chambon et al., April 30, 1992.   |
| WO 00/34783, Bergsma et al., June 15, 2000.    |
| WO 00/43791, Bamdad et al., July 27, 2000.     |
| WO 02/056022 A2, Bamdad et al., July 18, 2002. |

|   |
|---|
| WO 03/020279 A2, Bamdad, March 13, 2003.              |
| WO 03/020280 A2, Bamdad, March 13, 2003.              |
| WO 03/089451 A2, Hoogenboom et al., October 30, 2003. |
| WO 04/005470 A2, Payne et al., January 15, 2004.      |
| WO 05/019269 A2, Bamdad, March 3, 2005.               |
| WO 02/078598 A2, Wreschner et al., October 10, 2002.  |
| WO 95/24929, Mathiowitz et al., September 21, 1995.   |
| WO 03/070701 A2, Bergnes et al., August 28, 2003.     |
| WO 03/097053 A1, Feng et al., November 27, 2003.      |
| WO 04/055008 A1, Bergnes et al., July 1, 2004.        |
| WO 05/051922 A1, Wang et al., June 6, 2005.           |
| WO 02/22685 A2, Kufe et al., March 21, 2002.          |

It is respectfully requested that the Examiner indicate consideration of the cited references by returning copies of the attached forms [PTO/SB/08A] and [PTO/SB/08A] (substitutes for form 1449/PTO) with initials or other appropriate marks, and that the references be made of record as cited references in the application.

The Commissioner is authorized to charge JHK Law's Deposit Account No. **502486** for any fees required under 37 CFR §§ 1.16 and 1.17 and to credit any overpayment to said Deposit Account No. **502486**.

Respectfully submitted,

JHK Law

Dated: October 11, 2011

By: /Joseph Hyosuk Kim/  
Joseph Hyosuk Kim, Ph.D.  
Reg. No. 41,425  
Attorney for Applicants

**JHK Law**  
P.O. Box 1078  
La Canada, CA 91012-1078  
Telephone: (818) 249-8177;  
Facsimile: (818) 249-8277